Press Releases
Alzheon Publishes New Analyses from Phase 3 Studies Showing Clinical Benefit of Tramiprosate in Alzheimer’s Patients Who Are Carriers of APOE4, the Major Genetic Risk Factor in up to 65 Percent of Alzheimer’s Patients
Data published in The Journal of the Prevention of Alzheimer’s Disease is the first report to associate efficacy of an amyloid-targeted drug with the number of [...]
Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer’s Patients with APOE4/4 Homozygous Genotype
Pharmacokinetic and Safety Data from Phase 1b Studies with ALZ-801, an Optimized Prodrug of Tramiprosate, Presented at the Alzheimer's Association International Conference FRAMINGHAM, Mass., July 25, [...]
Alzheon Announces Efficacy Analyses of Prior Tramiprosate Phase 3 Studies Showing Clinically Meaningful Benefits on Key Clinical Endpoints in Alzheimer’s Disease Patients with APOE4 Genotype
Results Support Advancement of ALZ‐801 into Pivotal Clinical Studies in APOE4/4 Homozygous Subjects with Mild to Moderate Alzheimer’s Disease Data Presented at the 14th Annual International [...]
Alzheon Announces Presentations at Two Upcoming Investor Conferences
FRAMINGHAM, Mass., November 12, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, [...]
Alzheon Announces Efficacy Outcomes from Two Prior Tramiprosate Phase 3 Studies
Patients with Mild to Moderate Alzheimer’s Disease and APOE4/4 Genotype ShowedRobust and Sustained Efficacy on Cognitive and Functional Co‐Primary Outcomes over 78 weeks with Favorable Safety [...]
Alzheon Announces Initiation of Clinical Studies with ALZ‐801 Bridging to Pivotal Phase 3 Study in Alzheimer’s Disease
Phase 1b Multiple Dose‐Ranging Study and Tablet Bioequivalence Study Will Provide Clinical Dose and Tablet Formulation Data to Support ALZ‐801 Phase 3 Program FRAMINGHAM, Mass., November [...]